Atossa Genetics Inc. (NASDAQ:ATOS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) have earned an average rating of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $68.3333.

Several research analysts recently commented on the company. HC Wainwright raised their target price on Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Atossa Genetics by 4.2% in the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after purchasing an additional 245,717 shares during the period. Ameriprise Financial Inc. acquired a new position in Atossa Genetics during the second quarter worth $2,468,000. Renaissance Technologies LLC raised its stake in Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares in the last quarter. Geode Capital Management LLC raised its stake in Atossa Genetics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock worth $810,000 after acquiring an additional 9,627 shares in the last quarter. Finally, State Street Corp raised its stake in Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after acquiring an additional 141,990 shares in the last quarter. 12.74% of the stock is owned by institutional investors.

Atossa Genetics Price Performance

Shares of ATOS stock opened at $4.88 on Wednesday. The stock has a market cap of $42.02 million, a P/E ratio of -1.36 and a beta of 1.34. Atossa Genetics has a one year low of $3.76 and a one year high of $19.35. The stock has a fifty day moving average price of $5.08 and a 200 day moving average price of $9.53.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.